XPO1 and plasma cell myeloma: Promising advances have been reported in the clinical use of SINE derivatives KPT-330, KPT-8602, and SL-80, and especially the use of KPT-330 as a CRM1 inhibitor in the treatment of multiple myeloma has been approved by the Food and Drug Administration (FDA) [19].